Tysabri relaunch mooted for next year
In a report prepared by NCB Stockbrokers, senior analyst Dr Orla Hartford has reviewed the data available in Elan drug Tysabri's Biological License Application (BLA) in an attempt to understand why PML developed in two multiple sclerosis patients on Tysabri and AVONEX combination treatment.
The analysis revealed that, after a relatively short period of combination treatment, AVONEX had a significant effect on the accumulation, clearance and half-life of Tysabri and essentially led to almost double the intended Tysabri concentration after only 20 weeks of treatment.
